FDA Peptide Reclassification 2026: What It Means for Providers The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives